Citation(s)
- Agarwal K, Ahn SH, Elkhashab M, Kim K, Lau AH, Gaggar A, et al
Safety and efficacy ofvesatolimod (GS-9620) in patients with chronic hepatitis B (CHB) who are not currently on antiviral treatment. Poster 930. AASLD 2017. Hepatology; 66:497A 498A, 2017.
- Agarwal K, Ahn SH, Elkhashab M, Lau AH, Gaggar A, Bulusu A, Tian X, Cathcart AL, Woo J, Subramanian GM, Andreone P, Kim HJ, Chuang WL, Nguyen MH
Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on an
- Lau A, Joshi A, Nguyen AH, Gaggar A, Patterson SD, Woo J
Peripheral blood immune cell profiling in virally suppressed chronic hepatitis B (CHB) patients and CHB patients not on an oral antiviral therapy. HBV International Meeting 2017.
- Younossi ZM, Stepanova M, Janssen H, Agarwal K, Nguyen MH, Gane EJ, et al
The impact of treatment of chronic hepatitis B (CHB) on patient reported outcomes (PROs). Poster 1924. AASLD 2017. Hepatology; 66:1020A, 2017.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment
Details for clinical trial NCT02579382
